Abingdon Health PLC Publication of an article regarding AbC-19 (5275G)
July 27 2021 - 01:00AM
UK Regulatory
TIDMABDX
RNS Number : 5275G
Abingdon Health PLC
27 July 2021
AbC-19(TM) IgG LFD successfully used semi-quantitively to
monitor vaccine responses to variant proteins
- AbC-19(TM) able to detect different levels of antibody
response to the AstraZeneca and Pfizer vaccines as well as those
post-infection
- Antibody testing has the potential to be a key tool in
maintaining public safety, confidence in the vaccines and
supporting effective vaccine booster campaigns
York, U.K. 27 July 2021: Abingdon Health plc (AIM: ABDX)
("Abingdon" or "the Company"), a leading international developer
and manufacturer of high quality and effective rapid tests, is
pleased to note the publication of an article illustrating the use
of the AbC-19(TM) IgG spike antibody lateral flow device
(AbC-19(TM) LFD) in semi-quantitative format and antibody responses
against covid variants of concern.
The article demonstrates that AbC-19 (TM) is able to monitor
antibody response following vaccination or natural infection. The
paper shows differences in strength of antibody response with the
Pfizer and AstraZeneca ("AZ") vaccines and the induced antibody
responses to the original Wuhan variant, on which the vaccines are
based. It also shows that these antibodies cross-react to the
'spike protein' of different variants of concern. This study was
conducted using the AbC-19(TM) LFD and prototypes based on
different covid variants. The results demonstrated a stronger
antibody response in those vaccinated by Pfizer, compared to AZ,
whilst noting the cohort vaccinated with AZ were older, which the
authors noted may have an effect on antibody response.
The authors used a semi-quantitative score card to record the
strength of the test-line response on the LFD. They illustrated
pictorially and in graphical format a proportional response of line
intensity to the concentrations of neutralising antibodies in a
serial dilution of the WHO standard 20/136 from 1000 IU/mL down to
7.8 IU/mL which covers the range that previous research has shown
to be indicative of immunity. (The WHO standard 20/136 is for the
calibration and harmonization of serological assays detecting
anti-SARS-CoV-2 neutralising antibodies).
The article by researchers at the University of Birmingham is
published as: Ebanks, D et al, "Cross reactivity of serological
response to SARS-CoV-2 vaccination with viral variants of concern
detected by lateral flow immunoassays" Journal of Infection on
26(th) July 2021. To view the full paper, please click here.
Chris Yates, Chief Executive Officer of Abingdon Health
commented: "With the successful roll-out of vaccinations in the UK
and many other countries, it is now imperative that we monitor the
neutralising antibody levels in the worldwide population to
maintain the safety of the public and instill confidence in people
as they return to normal life. This study demonstrates how
AbC-19(TM) can be used to monitor antibody response alongside
vaccines as well as the neutralising antibody response following
natural infection. The AbC-19(TM) test will allow individuals to
know their own status, which is becoming a growing concern, and
allow healthcare agencies and healthcare professionals worldwide to
manage the continued vaccination roll-out and to develop effective
and targeted booster vaccination programmes. The study also shows
the ability of our scientists to pivot the format of the test if
other variants of concern present which generate a different
antibody response.
Importantly, due to the utility of the score card used alongside
the AbC-19(TM) test for these applications, Abingdon intends to
make a supplementary product available, initially for research use
only, in August which provides a semi-quantitative result which
will may indicate the strength of antibody response and possibly
immunity."
Enquiries:
Abingdon Health plc
Chris Yates Chief Executive Officer Via Consilium
Dr Chris Hand Non-Executive Chairman
Melanie Ross Chief Financial Officer
Consilium Financial PR Tel: +44 (0) 7720 088 468
Matthew Neal abingdonhealth@consilium-comms.com
Mary-Jane Elliott
Davide Salvi
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R), a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
https://www.abingdonhealth.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUNRARABUBUUR
(END) Dow Jones Newswires
July 27, 2021 02:00 ET (06:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2023 to Mar 2024